Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2025)
Historic Finished Goods for Catalyst Pharmaceuticals (CPRX) over the last 3 years, with Q3 2025 value amounting to $11.3 million.
- Catalyst Pharmaceuticals' Finished Goods rose 2216.81% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year increase of 2216.81%. This contributed to the annual value of $9.6 million for FY2024, which is 455.19% up from last year.
- As of Q3 2025, Catalyst Pharmaceuticals' Finished Goods stood at $11.3 million, which was up 2216.81% from $8.1 million recorded in Q2 2025.
- Catalyst Pharmaceuticals' Finished Goods' 5-year high stood at $11.3 million during Q3 2025, with a 5-year trough of $8.1 million in Q1 2025.
- Its 3-year average for Finished Goods is $9.1 million, with a median of $9.2 million in 2023.
- The largest annual percentage gain for Catalyst Pharmaceuticals' Finished Goods in the last 5 years was 2216.81% (2025), contrasted with its biggest fall of 328.77% (2025).
- Over the past 3 years, Catalyst Pharmaceuticals' Finished Goods (Quarter) stood at $9.2 million in 2023, then increased by 4.55% to $9.6 million in 2024, then increased by 17.9% to $11.3 million in 2025.
- Its Finished Goods was $11.3 million in Q3 2025, compared to $8.1 million in Q2 2025 and $8.1 million in Q1 2025.